Page 30«..1020..29303132..4050..»

Artificial sweeteners dont aid weight loss, may increase diabetes, heart disease risk, says WHO – ThePrint

Posted: May 17, 2023 at 12:07 am

  1. Artificial sweeteners dont aid weight loss, may increase diabetes, heart disease risk, says WHO  ThePrint
  2. World Health Organization warns nonsugar sweeteners may increase risk of diabetes and heart disease  MarketWatch
  3. WHO: Artificial sweeteners linked to diabetes, death  POLITICO Europe

Visit link:
Artificial sweeteners dont aid weight loss, may increase diabetes, heart disease risk, says WHO - ThePrint

Posted in Diabetes | Comments Off on Artificial sweeteners dont aid weight loss, may increase diabetes, heart disease risk, says WHO – ThePrint

How Does Gene Therapy Work? Types, Uses, Safety – Healthline

Posted: May 9, 2023 at 12:11 am

Gene therapy may have the potential to fix or replace genetic mutations, which are changes in your DNA that affect how your body works.

Doctors use gene therapy, also called gene editing to directly alter your genes.

This approach may help treat diseases caused by a single mutation, such as beta-thalassemia or spinal muscular atrophy (SMA). Gene editing may also help treat certain cancers.

Gene editing tools such as CRISPR-Cas9 are very new and are rapidly changing. Researchers continue to study their full potential along with any risks they may pose.

Heres what experts know so far about gene therapy.

Genes are small segments of DNA that instruct your cells to make certain proteins when specific conditions are met.

Mutated genes, on the other hand, may cause your cells to make too much or too little of the necessary protein. Even small changes can have a domino effect across your body just as tiny changes in computer code can affect an entire program.

Gene therapy can address this issue by:

Scientists dont have tweezers small enough to edit your DNA by hand. Instead, they recruit a surprising ally to work on their behalf: viruses.

Typically, a virus would enter your cells and alter your DNA to create more copies of itself. But scientists can switch out this programming with their own, hijacking the virus to heal instead of harm. These vectors, as theyre called, dont have the parts they need to cause disease, so they cant make you sick the way a regular virus could.

There are two types of gene therapy:

Each type has its own benefits:

Gene therapy is different from genetic engineering, which means changing otherwise healthy DNA for the purpose of enhancing specific traits. Hypothetically, genetic engineering could potentially reduce a childs risk of certain diseases or change the color of their eyes. But the practice remains highly controversial since it hovers very close to eugenics.

Gene therapy may be used to treat a variety of genetic conditions, including:

When the RPE65 gene in your retinas doesnt work, your eyeballs cant convert light to electrical signals.

The gene therapy Luxturna, approved by the Food and Drug Administration (FDA) in 2017, can deliver a functional replacement of the RPE64 gene to your retinal cells.

The FDA-approved Hemgenix can treat the bleeding disorder hemophilia B. The viral vector instructs your liver cells to create more of the factor IX protein, which helps your blood clot.

Meanwhile, the gene therapy Zynteglo, approved by the FDA in 2022, treats beta-thalassemia by giving your bone marrow stem cells correct instructions for creating hemoglobin.

This blood disorder can lower the oxygen in your body because it decreases your bodys hemoglobin production.

In infantile-onset SMA, an infants body cant make enough of the survival of motor neuron (SMN) proteins necessary to build and repair motor neurons. Without these neurons, infants gradually lose their ability to move and breathe.

The gene therapy Zolgensma, approved by the FDA in 2019, replaces faulty SMN1 genes in an infants motor cells with genes that can create enough SMN proteins.

Your ABCD1 gene produces an enzyme that breaks down fatty acids in your brain. If you have cerebral adrenoleukodystrophy, this gene is either broken or missing.

Skysona, FDA approved as of 2022, delivers a functional ABCD1 gene so that fatty acids dont build up and cause brain damage.

The FDA has approved gene therapies to treat multiple types of cancer, such as non-Hodgkins lymphoma and multiple myeloma.

Most cancer gene therapies work indirectly by inserting new genes into a powerful antibody called a T cell. Your changed T cells can then latch on to cancerous cells and eliminate them, similar to how they attack viruses.

The therapy Adstiladrin, approved by the FDA in 2022, can treat nonmuscle-invasive bladder cancer by altering the DNA in your bladder cells themselves.

Some people considering gene therapy may feel uneasy about putting viruses in their body.

Keep in mind, though, that gene therapies undergo extensive testing before approval. The viruses in gene therapies are also fixed so they cant replicate similar to many vaccines.

That said, gene therapies may pose other risks:

Despite these issues, experts generally believe gene therapy offers more benefits than risks.

Most of the conditions treated with gene therapy are life threatening. The dangers of leaving them untreated often outweigh the risks of potential side effects.

Gene therapy does come with a few drawbacks that keep it from becoming a widespread treatment.

Gene therapy can only target certain mutations. This means it may not work for everyone with a specific condition.

For example, two people may have inherited vision loss. Currently, gene therapy can only treat vision loss caused by the RPE64 mutation.

Because gene therapy research is so new, experts do extensive safety testing before introducing their treatments to the public. It can take years to get FDA approval for each new therapy.

As you might imagine, gene therapies are expensive to manufacture and administer. This not only affects funding for clinical trials but also the price of the drug.

For example, the gene therapy Zolgensma is the most expensive drug in the United States at $2.1 million per dose. Even with insurance, that kind of price tag remains out of reach for the average American.

Scientists are trying to find ways to make the development process safer, cheaper, and more efficient so more people can access gene therapy.

Gene therapy works to treat several different genetic diseases by editing the mutations that cause them. As researchers further refine and expand this technology, they may find even more conditions that could be treated with it.

Experts are also continuing to explore options to make gene therapy more affordable so people who need these treatments have an easier time getting them.

Emily Swaim is a freelance health writer and editor who specializes in psychology. She has a BA in English from Kenyon College and an MFA in writing from California College of the Arts. In 2021, she received her Board of Editors in Life Sciences (BELS) certification. You can find more of her work on GoodTherapy, Verywell, Investopedia, Vox, and Insider. Find her on Twitter and LinkedIn.

See original here:
How Does Gene Therapy Work? Types, Uses, Safety - Healthline

Posted in Gene therapy | Comments Off on How Does Gene Therapy Work? Types, Uses, Safety – Healthline

Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

Posted: May 9, 2023 at 12:10 am

First Wave of Investigational RAS(ON) Inhibitors – RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) – progressing on plan

See more here:
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

Posted in Global News Feed | Comments Off on Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

Shockwave Medical Reports First Quarter 2023 Financial Results

Posted: May 9, 2023 at 12:10 am

SANTA CLARA, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2023.

Here is the original post:
Shockwave Medical Reports First Quarter 2023 Financial Results

Posted in Global News Feed | Comments Off on Shockwave Medical Reports First Quarter 2023 Financial Results

Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

Posted: May 9, 2023 at 12:10 am

-- Positive Data from VAX-24 Phase 2 Study in Adults Aged 65 and Older Demonstrated Robust Immune Responses Across all 24 Serotypes (ST) at all Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64 ---- Full Six-Month Safety Data from Both Adult Studies Demonstrated VAX-24 Safety and Tolerability Results Similar to PCV20 at All Doses Studied --

More:
Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

Posted in Global News Feed | Comments Off on Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights

Posted: May 9, 2023 at 12:10 am

– UDENYCA® autoinjector approved and ready for May 2023 launch –– CIMERLI® product-specific Q-code now facilitating electronic reimbursement following April 1 activation –– FDA inspection of toripalimab manufacturing site scheduled for May 2023 –– Toripalimab launch anticipated in Q3 2023, if approved –– YUSIMRY™ ready for planned July 2023 launch –– FDA review of UDENYCA® OBI BLA supplement progressing; launch anticipated in 2023, if approved –– Net product revenue of $32.4 million in the first quarter 2023 –– Conference call today at 5:00 p.m. Eastern Time –

See the original post here:
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights

Posted in Global News Feed | Comments Off on Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights

Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET

Posted: May 9, 2023 at 12:10 am

CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2023 financial results will be released on Monday, May 15, 2023 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Go here to see the original:
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET

Posted in Global News Feed | Comments Off on Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET

NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant…

Posted: May 9, 2023 at 12:10 am

SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) --  NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that results of a Phase 2 investigator-sponsored trial of aldafermin for the treatment of patients with idiopathic BAM with IBS-D were presented at Digestive Disease Week 2023.

Read the rest here:
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant...

Posted in Global News Feed | Comments Off on NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant…

ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

Posted: May 9, 2023 at 12:10 am

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

Read more:
ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

Posted in Global News Feed | Comments Off on ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

Posted: May 9, 2023 at 12:10 am

EMERYVILLE, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today it will participate in the following upcoming investor conferences:

Follow this link:
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

Posted in Global News Feed | Comments Off on 4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

Page 30«..1020..29303132..4050..»